Part 1of the study will evaluate the safety, pharmacokinetics, pharmacodynamics and
immunogenicity of increasing doses of a vaccine-based immunotherapy regimen (VBIR-2) for
patients with advanced or metastatic non-small cell lung cancer and metastatic
triple-negative breast cancer.
Part 2 will evaluate the safety, pharmacokinetics and pharmacodynamics, immunogenicity
and preliminary evidence of efficacy of the Expansion dose of VBIR-2 in participants with
advanced or metastatic non-small cell lung cancer.
Study sponsor and potential other locations can be found on ClinicalTrials.gov for NCT03674827.
Locations matching your search criteria
United States
Kansas
Fairway
University of Kansas Clinical Research CenterStatus: Active
Name Not Available
Westwood
University of Kansas Hospital-Westwood Cancer CenterStatus: Active
Name Not Available
The study is divided into two parts, Dose Escalation (Part 1) in participants with NSCLC
and TNBC without acceptable alternative treatment options, followed by Dose Expansion
(Part 2) in participants with NSCLC who have progressed on or after treatment with
platinum-based chemotherapy and treatment with 1 immune checkpoint inhibitor, given
concurrently or sequentially with chemotherapy.
Part 1 has been completed.
Lead OrganizationPfizer Inc